Recent Updates — IPHA

Innate Pharma reported a net loss of €19.6 million for the first half of 2026 and announced two material post-period events. The company closed a strategic partnership with Sobi for lacutamab, receiving a $75 million upfront payment on September 16, 2026, which triggers the initiation of the TELLOMAK-3 Phase 3 study in cutaneous T-cell lymphoma. Additionally, Innate Pharma completed a €30 million equity financing via private placement of approximately 17.6 million shares at €1.70 per share on August 18, 2026. These proceeds extend the company's cash runway through Q1 2028. The firm also appointed Markus Jensen as Chief Medical Officer effective September 1, 2026. Innate Pharma is a clinical-stage biotechnology company developing immunotherapies and antibody-drug conjugates for cancer treatment.

Innate Pharma SA reported a net loss of €19.6 million for the first half of 2026, compared to a €21.3 million loss in the prior year period. Revenue and other income increased by €0.8 million to €5.7 million, driven primarily by collaboration revenue from Sanofi totaling €3.1 million and research tax credits of €2.5 million. Operating expenses decreased by €5.6 million to €24.7 million, reflecting a reduction in R&D spending due to the completion of lacutamab trials and discontinuation of certain preclinical studies, as well as lower general expenses following workforce reductions. Cash and cash equivalents declined to €6.5 million from €10.9 million at year-end 2025, while net financial assets stood at €21.4 million. The company maintains a collaboration debt of €39.6 million with AstraZeneca for the monalizumab program. Innate Pharma SA is a clinical-stage biotechnology company developing immunotherapies and antibody-drug conjugates for cancer treatment.

Innate Pharma SA announced that its strategic partnership with Sobi is now effective following the expiration of antitrust waiting periods and completion of other conditions. The closing triggers a USD 75 million upfront payment to Innate Pharma. This event marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study for lacutamab in cutaneous T-cell lymphoma, with the first patient expected in Q1 2027. Under the agreement, Sobi holds exclusive global commercialization rights upon potential accelerated approval and may assume full development rights following positive Phase 3 results. Innate Pharma is a clinical-stage biotechnology company developing immunotherapies for cancer patients.